Shots:

• Xencor to receive $120M upfront- $160M milestones for XmAb24306 program and $180M for IL-15 candidate. Genentech to get worldwide commercialization rights for XmAb24306 & IL-15 program- with Xencor has an option for its co-promotion in the US- sharing equal cost/profit
• The companies will collaborate for a two-year research program for discovering IL-15 drug candidates- with its expected closure in H1’19
• XmAb24306 is an IL-15/IL-15Rα cytokine- developed using Xencor’s Fc domain and Xtend Fc technology evaluated in preclinical trials for multiple cancer

 Ref: PRNewswire | Image: Fatherly